Amedeo Smart

Free Medical Literature Service


 

Amedeo

Ovarian Neoplasms

  Free Subscription

Articles published in
Br J Cancer
    September 2022
  1. OCHS-BALCOM HM, Johnson C, Guertin KA, Qin B, et al
    Racial differences in the association of body mass index and ovarian cancer risk in the OCWAA Consortium.
    Br J Cancer. 2022 Sep 22. pii: 10.1038/s41416-022-01981.
    >> Share

  2. CHEN Y, Wang DD, Wu YP, Su D, et al
    Correction To: MDM2 promotes epithelial-mesenchymal transition and metastasis of ovarian cancer SKOV3 cells.
    Br J Cancer. 2022 Sep 15. pii: 10.1038/s41416-022-01984.
    >> Share

  3. ABIKO K, Hamanishi J, Matsumura N, Mandai M, et al
    Dynamic host immunity and PD-L1/PD-1 blockade efficacy: developments after "IFN-gamma from lymphocytes induces PD-L1 expression and promotes progression of ovarian cancer".
    Br J Cancer. 2022 Sep 6. pii: 10.1038/s41416-022-01960.
    >> Share

    August 2022
  4. GAHLAWAT AW, Witte T, Haarhuis L, Schott S, et al
    A novel circulating miRNA panel for non-invasive ovarian cancer diagnosis and prognosis.
    Br J Cancer. 2022 Aug 5. pii: 10.1038/s41416-022-01925.
    >> Share

    July 2022
  5. NICHOLSON HA, Sawers L, Clarke RG, Hiom KJ, et al
    Fibroblast growth factor signalling influences homologous recombination-mediated DNA damage repair to promote drug resistance in ovarian cancer.
    Br J Cancer. 2022 Jul 1. pii: 10.1038/s41416-022-01899.
    >> Share

    June 2022
  6. SASAMOTO N, Wang T, Townsend MK, Eliassen AH, et al
    Pre-diagnosis and post-diagnosis dietary patterns and survival in women with ovarian cancer.
    Br J Cancer. 2022 Jun 27. pii: 10.1038/s41416-022-01901.
    >> Share

  7. BEINSE G, Just PA, Le Frere Belda MA, Laurent-Puig P, et al
    Discovery and validation of a transcriptional signature identifying homologous recombination-deficient breast, endometrial and ovarian cancers.
    Br J Cancer. 2022 Jun 25. pii: 10.1038/s41416-022-01900.
    >> Share

  8. KAMAT K, Krishnan V, Dorigo O
    Macrophage-derived CCL23 upregulates expression of T-cell exhaustion markers in ovarian cancer.
    Br J Cancer. 2022 Jun 24. pii: 10.1038/s41416-022-01887.
    >> Share

  9. HOLLIS RL, Croy I, Churchman M, Bartos C, et al
    Ovarian carcinosarcoma is a distinct form of ovarian cancer with poorer survival compared to tubo-ovarian high-grade serous carcinoma.
    Br J Cancer. 2022 Jun 17. pii: 10.1038/s41416-022-01874.
    >> Share

  10. KOTSOPOULOS J, Zamani N, Rosen B, McLaughlin JR, et al
    Impact of germline mutations in cancer-predisposing genes on long-term survival in patients with epithelial ovarian cancer.
    Br J Cancer. 2022 Jun 16. pii: 10.1038/s41416-022-01840.
    >> Share

    May 2022
  11. MENON U, Weller D, Falborg AZ, Jensen H, et al
    Diagnostic routes and time intervals for ovarian cancer in nine international jurisdictions; findings from the International Cancer Benchmarking Partnership (ICBP).
    Br J Cancer. 2022 May 26. pii: 10.1038/s41416-022-01844.
    >> Share

  12. CHEN T, Yu T, Zhuang S, Geng Y, et al
    Upregulation of CXCL1 and LY9 contributes to BRCAness in ovarian cancer and mediates response to PARPi and immune checkpoint blockade.
    Br J Cancer. 2022 May 26. pii: 10.1038/s41416-022-01836.
    >> Share

  13. EL HELALI A, Plummer R, Jayson GC, Coyle VM, et al
    A first-in-human Phase I dose-escalation trial of the novel therapeutic peptide, ALM201, demonstrates a favourable safety profile in unselected patients with ovarian cancer and other advanced solid tumours.
    Br J Cancer. 2022 May 14. pii: 10.1038/s41416-022-01780.
    >> Share

    April 2022
  14. CREMONA M, Vandenberg CJ, Farrelly AM, Madden SF, et al
    BRCA mutations lead to XIAP overexpression and sensitise ovarian cancer to inhibitor of apoptosis (IAP) family inhibitors.
    Br J Cancer. 2022 Apr 30. pii: 10.1038/s41416-022-01823.
    >> Share

  15. KOIZUME S, Takahashi T, Nakamura Y, Yoshihara M, et al
    Lipophagy-ICAM-1 pathway associated with fatty acid and oxygen deficiencies is involved in poor prognoses of ovarian clear cell carcinoma.
    Br J Cancer. 2022 Apr 21. pii: 10.1038/s41416-022-01808.
    >> Share

  16. SHAKFA N, Li D, Nersesian S, Wilson-Sanchez J, et al
    The STING pathway: Therapeutic vulnerabilities in ovarian cancer.
    Br J Cancer. 2022 Apr 5. pii: 10.1038/s41416-022-01797.
    >> Share

  17. KONSTANTINOPOULOS PA, Cheng SC, Supko JG, Polak M, et al
    Combined PARP and HSP90 inhibition: preclinical and Phase 1 evaluation in patients with advanced solid tumours.
    Br J Cancer. 2022;126:1027-1036.
    >> Share

    March 2022
  18. YOU B, Van Wagensveld L, Tod M, Sonke GS, et al
    Low probability of disease cure in advanced ovarian carcinomas before the PARP inhibitor era.
    Br J Cancer. 2022 Mar 31. pii: 10.1038/s41416-022-01732.
    >> Share

  19. SEITZ S, Dreyer TF, Stange C, Steiger K, et al
    CXCL9 inhibits tumour growth and drives anti-PD-L1 therapy in ovarian cancer.
    Br J Cancer. 2022 Mar 21. pii: 10.1038/s41416-022-01763.
    >> Share

  20. MORGAN RD, Burghel GJ, Flaum N, Bulman M, et al
    BRCA1/2 in non-mucinous epithelial ovarian cancer: tumour with or without germline testing?
    Br J Cancer. 2022 Mar 8. pii: 10.1038/s41416-022-01773.
    >> Share

    February 2022
  21. ROQUE DM, Siegel ER, Buza N, Bellone S, et al
    Randomised phase II trial of weekly ixabepilone +/- biweekly bevacizumab for platinum-resistant or refractory ovarian/fallopian tube/primary peritoneal cancer.
    Br J Cancer. 2022 Feb 11. pii: 10.1038/s41416-022-01717.
    >> Share

    January 2022
  22. YE S, Li Q, Wu Y, Jiang W, et al
    Integrative genomic and transcriptomic analysis reveals immune subtypes and prognostic markers in ovarian clear cell carcinoma.
    Br J Cancer. 2022 Jan 18. pii: 10.1038/s41416-022-01705.
    >> Share

  23. MUKAMA T, Fortner RT, Katzke V, Hynes LC, et al
    Prospective evaluation of 92 serum protein biomarkers for early detection of ovarian cancer.
    Br J Cancer. 2022 Jan 14. pii: 10.1038/s41416-021-01697.
    >> Share

  24. SUN J, Yan C, Xu D, Zhang Z, et al
    Immuno-genomic characterisation of high-grade serous ovarian cancer reveals immune evasion mechanisms and identifies an immunological subtype with a favourable prognosis and improved therapeutic efficacy.
    Br J Cancer. 2022 Jan 11. pii: 10.1038/s41416-021-01692.
    >> Share

    December 2021
  25. FOTOPOULOU C, Rockall A, Lu H, Lee P, et al
    Validation analysis of the novel imaging-based prognostic radiomic signature in patients undergoing primary surgery for advanced high-grade serous ovarian cancer (HGSOC).
    Br J Cancer. 2021 Dec 18. pii: 10.1038/s41416-021-01662.
    >> Share

    November 2021
  26. BYUN D, Hong S, Ryu S, Nam Y, et al
    Early-life body mass index and risks of breast, endometrial, and ovarian cancers: a dose-response meta-analysis of prospective studies.
    Br J Cancer. 2021 Nov 12. pii: 10.1038/s41416-021-01625.
    >> Share

  27. GUFFANTI F, Alvisi MF, Anastasia A, Ricci F, et al
    Basal expression of RAD51 foci predicts olaparib response in patient-derived ovarian cancer xenografts.
    Br J Cancer. 2021 Nov 3. pii: 10.1038/s41416-021-01609.
    >> Share

    October 2021
  28. MURPHY AD, Morgan RD, Clamp AR, Jayson GC, et al
    The role of vascular endothelial growth factor inhibitors in the treatment of epithelial ovarian cancer.
    Br J Cancer. 2021 Oct 29. pii: 10.1038/s41416-021-01605.
    >> Share

  29. BLACKFORD AL, Childs EJ, Porter N, Petersen GM, et al
    A risk prediction tool for individuals with a family history of breast, ovarian, or pancreatic cancer: BRCAPANCPRO.
    Br J Cancer. 2021 Oct 26. pii: 10.1038/s41416-021-01580.
    >> Share

  30. SI S, Li J, Tewara MA, Li H, et al
    Identifying causality, genetic correlation, priority and pathways of large-scale complex exposures of breast and ovarian cancers.
    Br J Cancer. 2021 Oct 20. pii: 10.1038/s41416-021-01576.
    >> Share

    September 2021
  31. CRISPIN-ORTUZAR M, Sala E
    Precision radiogenomics: fusion biopsies to target tumour habitats in vivo.
    Br J Cancer. 2021;125:778-779.
    >> Share

    June 2021
  32. FENG JL, Dixon-Suen SC, Jordan SJ, Webb PM, et al
    Statin use and survival among women with ovarian cancer: an Australian national data-linkage study.
    Br J Cancer. 2021 Jun 16. pii: 10.1038/s41416-021-01460.
    >> Share

    May 2021
  33. XU X, Wang Y, Bryce NS, Tang K, et al
    Targeting the actin/tropomyosin cytoskeleton in epithelial ovarian cancer reveals multiple mechanisms of synergy with anti-microtubule agents.
    Br J Cancer. 2021 May 12. pii: 10.1038/s41416-021-01420.
    >> Share

    March 2021
  34. LEPAGE CC, Palmer MCL, Farrell AC, Neudorf NM, et al
    Reduced SKP1 and CUL1 expression underlies increases in Cyclin E1 and chromosome instability in cellular precursors of high-grade serous ovarian cancer.
    Br J Cancer. 2021 Mar 17. pii: 10.1038/s41416-021-01317.
    >> Share

  35. ZHANG X, Ling MT, Feng H, Wong YC, et al
    Retraction Note to: Id-1 stimulates cell proliferation through activation of EGFR in ovarian cancer cells.
    Br J Cancer. 2021 Mar 15. pii: 10.1038/s41416-021-01322.
    >> Share

  36. ARTHUR RS, Dannenberg AJ, Kim M, Rohan TE, et al
    The association of body fat composition with risk of breast, endometrial, ovarian and colorectal cancers among normal weight participants in the UK Biobank.
    Br J Cancer. 2021 Mar 15. pii: 10.1038/s41416-020-01210.
    >> Share

    February 2021
  37. BARCLAY ME, Abel GA, Greenberg DC, Rous B, et al
    Socio-demographic variation in stage at diagnosis of breast, bladder, colon, endometrial, lung, melanoma, prostate, rectal, renal and ovarian cancer in England and its population impact.
    Br J Cancer. 2021 Feb 9. pii: 10.1038/s41416-021-01279.
    >> Share

  38. HAYASHI T, Konishi I
    Correlation of anti-tumour drug resistance with epigenetic regulation.
    Br J Cancer. 2021;124:681-682.
    >> Share

    January 2021
  39. LU H, Cunnea P, Nixon K, Rinne N, et al
    Discovery of a biomarker candidate for surgical stratification in high-grade serous ovarian cancer.
    Br J Cancer. 2021 Jan 21. pii: 10.1038/s41416-020-01252.
    >> Share

  40. SALAS-BENITO D, Conde E, Tamayo-Uria I, Mancheno U, et al
    The mutational load and a T-cell inflamed tumour phenotype identify ovarian cancer patients rendering tumour-reactive T cells from PD-1(+) tumour-infiltrating lymphocytes.
    Br J Cancer. 2021 Jan 5. pii: 10.1038/s41416-020-01218.
    >> Share

  41. WINFIELD JM, Wakefield JC, Brenton JD, AbdulJabbar K, et al
    Biomarkers for site-specific response to neoadjuvant chemotherapy in epithelial ovarian cancer: relating MRI changes to tumour cell load and necrosis.
    Br J Cancer. 2021 Jan 4. pii: 10.1038/s41416-020-01217.
    >> Share

    December 2020
  42. AMERATUNGA M, Brana I, Bono P, Postel-Vinay S, et al
    First-in-human Phase 1 open label study of the BET inhibitor ODM-207 in patients with selected solid tumours.
    Br J Cancer. 2020;123:1730-1736.
    >> Share

    November 2020
  43. YAN S, Xuan J, Brajanovski N, Tancock MRC, et al
    The RNA polymerase I transcription inhibitor CX-5461 cooperates with topoisomerase 1 inhibition by enhancing the DNA damage response in homologous recombination-proficient high-grade serous ovarian cancer.
    Br J Cancer. 2020 Nov 11. pii: 10.1038/s41416-020-01158.
    >> Share

    October 2020
  44. MILLINGTON K, Hayes K, Pilcher S, Roberts S, et al
    A serous borderline ovarian tumour in a transgender male adolescent.
    Br J Cancer. 2020 Oct 27. pii: 10.1038/s41416-020-01129.
    >> Share

    September 2020
  45. KIM HS, Park SY, Park CY, Kim YT, et al
    A multicentre, randomised, open-label, parallel-group Phase 2b study of belotecan versus topotecan for recurrent ovarian cancer.
    Br J Cancer. 2020 Sep 30. pii: 10.1038/s41416-020-01098.
    >> Share

    August 2020
  46. PHELPS DL, Saso S, Ghaem-Maghami S
    Is ovarian cancer surgery stuck in the dark ages?: a commentary piece reviewing surgical technologies.
    Br J Cancer. 2020 Aug 24. pii: 10.1038/s41416-020-01035.
    >> Share

  47. YANG M, Zhang G, Wang Y, He M, et al
    Tumour-associated neutrophils orchestrate intratumoural IL-8-driven immune evasion through Jagged2 activation in ovarian cancer.
    Br J Cancer. 2020 Aug 11. pii: 10.1038/s41416-020-1026.
    >> Share

    July 2020
  48. METCALFE KA, Price MA, Mansfield C, Hallett DC, et al
    Predictors of long-term cancer-related distress among female BRCA1 and BRCA2 mutation carriers without a cancer diagnosis: an international analysis.
    Br J Cancer. 2020;123:268-274.
    >> Share

    June 2020
  49. MARTINS FC, Couturier DL, Paterson A, Karnezis AN, et al
    Clinical and pathological associations of PTEN expression in ovarian cancer: a multicentre study from the Ovarian Tumour Tissue Analysis Consortium.
    Br J Cancer. 2020 Jun 18. pii: 10.1038/s41416-020-0900.
    >> Share

  50. VAN WEELDEN WJ, van der Putten LJM, Inda MA, van Brussel A, et al
    Oestrogen receptor pathway activity is associated with outcome in endometrial cancer.
    Br J Cancer. 2020 Jun 8. pii: 10.1038/s41416-020-0925.
    >> Share

    May 2020
  51. JIANG YX, Siu MK, Wang JJ, Mo XT, et al
    Ascites-derived ALDH+CD44+ tumour cell subsets endow stemness, metastasis and metabolic switch via PDK4-mediated STAT3/AKT/NF-kappaB/IL-8 signalling in ovarian cancer.
    Br J Cancer. 2020 May 11. pii: 10.1038/s41416-020-0865.
    >> Share

  52. BOCHNER F, Fellus-Alyagor L, Ketter D, Golani O, et al
    Bimodal magnetic resonance and optical imaging of extracellular matrix remodelling by orthotopic ovarian tumours.
    Br J Cancer. 2020 May 11. pii: 10.1038/s41416-020-0878.
    >> Share

  53. FORD CE, Werner B, Hacker NF, Warton K, et al
    The untapped potential of ascites in ovarian cancer research and treatment.
    Br J Cancer. 2020 May 8. pii: 10.1038/s41416-020-0875.
    >> Share

    April 2020
  54. SKOLD C, Bjorge T, Ekbom A, Engeland A, et al
    Pregnancy-related risk factors for sex cord-stromal tumours and germ cell tumours in parous women: a registry-based study.
    Br J Cancer. 2020 Apr 27. pii: 10.1038/s41416-020-0849.
    >> Share

  55. MONTFORT A, Owen S, Piskorz AM, Supernat A, et al
    Combining measures of immune infiltration shows additive effect on survival prediction in high-grade serous ovarian carcinoma.
    Br J Cancer. 2020 Apr 6. pii: 10.1038/s41416-020-0822.
    >> Share

  56. ZHAO Y, He M, Cui L, Gao M, et al
    Chemotherapy exacerbates ovarian cancer cell migration and cancer stem cell-like characteristics through GLI1.
    Br J Cancer. 2020 Apr 3. pii: 10.1038/s41416-020-0825.
    >> Share

    February 2020
  57. MASOODI T, Siraj S, Siraj AK, Azam S, et al
    Genetic heterogeneity and evolutionary history of high-grade ovarian carcinoma and matched distant metastases.
    Br J Cancer. 2020 Feb 26. pii: 10.1038/s41416-020-0763.
    >> Share

  58. BERG HF, Ju Z, Myrvold M, Fasmer KE, et al
    Development of prediction models for lymph node metastasis in endometrioid endometrial carcinoma.
    Br J Cancer. 2020 Feb 10. pii: 10.1038/s41416-020-0745.
    >> Share

  59. ROBERTS C, Strauss VY, Kopijasz S, Gourley C, et al
    Results of a phase II clinical trial of 6-mercaptopurine (6MP) and methotrexate in patients with BRCA-defective tumours.
    Br J Cancer. 2020;122:483-490.
    >> Share

    January 2020
  60. HASEGAWA K, Shimada M, Takeuchi S, Fujiwara H, et al
    A phase 2 study of intraperitoneal carboplatin plus intravenous dose-dense paclitaxel in front-line treatment of suboptimal residual ovarian cancer.
    Br J Cancer. 2020 Jan 31. pii: 10.1038/s41416-020-0734.
    >> Share

  61. WHITWELL HJ, Worthington J, Blyuss O, Gentry-Maharaj A, et al
    Improved early detection of ovarian cancer using longitudinal multimarker models.
    Br J Cancer. 2020 Jan 15. pii: 10.1038/s41416-019-0718.
    >> Share

  62. HORIKAWA N, Abiko K, Matsumura N, Baba T, et al
    Anti-VEGF therapy resistance in ovarian cancer is caused by GM-CSF-induced myeloid-derived suppressor cell recruitment.
    Br J Cancer. 2020 Jan 14. pii: 10.1038/s41416-019-0725.
    >> Share

  63. LIU N, Lin X, Huang C
    Activation of the reverse transsulfuration pathway through NRF2/CBS confers erastin-induced ferroptosis resistance.
    Br J Cancer. 2020;122:279-292.
    >> Share

    December 2019
  64. GENESTIE C, Blanc-Durand F, Auguste A, Pautier P, et al
    Clinical utility of SMARCA4 testing by immunohistochemistry in rare ovarian tumours.
    Br J Cancer. 2019 Dec 17. pii: 10.1038/s41416-019-0687.
    >> Share

  65. BENGTSEN MB, Veres K, Norgaard M
    First-time postmenopausal bleeding as a clinical marker of long-term cancer risk: A Danish Nationwide Cohort Study.
    Br J Cancer. 2019 Dec 6. pii: 10.1038/s41416-019-0668.
    >> Share

    November 2019
  66. TUNA M, Ju Z, Yoshihara K, Amos CI, et al
    Clinical relevance of TP53 hotspot mutations in high-grade serous ovarian cancers.
    Br J Cancer. 2019 Nov 29. pii: 10.1038/s41416-019-0654.
    >> Share

  67. ANNETT S, Moore G, Short A, Marshall A, et al
    FKBPL-based peptide, ALM201, targets angiogenesis and cancer stem cells in ovarian cancer.
    Br J Cancer. 2019 Nov 27. pii: 10.1038/s41416-019-0649.
    >> Share

    October 2019
  68. HAMESTER F, Legler K, Wichert B, Kelle N, et al
    Prognostic relevance of the Golgi mannosidase MAN1A1 in ovarian cancer: impact of N-glycosylation on tumour cell aggregation.
    Br J Cancer. 2019 Oct 29. pii: 10.1038/s41416-019-0607.
    >> Share

    September 2019
  69. ZHAO J, Giri A, Zhu X, Shrubsole MJ, et al
    Calcium: magnesium intake ratio and colorectal carcinogenesis, results from the prostate, lung, colorectal, and ovarian cancer screening trial.
    Br J Cancer. 2019 Sep 23. pii: 10.1038/s41416-019-0579.
    >> Share

    July 2019
  70. LEVASSEUR N, Chia S
    Cancer screening and prevention in BRCA mutation carriers: a missed opportunity?
    Br J Cancer. 2019;121:1-2.
    >> Share

  71. BERNDSEN RH, Castrogiovanni C, Weiss A, Rausch M, et al
    Anti-angiogenic effects of crenolanib are mediated by mitotic modulation independently of PDGFR expression.
    Br J Cancer. 2019;121:139-149.
    >> Share

    June 2019
  72. PLUMMER C, Michael A, Shaikh G, Stewart M, et al
    Expert recommendations on the management of hypertension in patients with ovarian and cervical cancer receiving bevacizumab in the UK.
    Br J Cancer. 2019 Jun 11. pii: 10.1038/s41416-019-0481.
    >> Share


Free Medical Abstracts
Privacy Policy
Sponsors
Share

© Amedeo 1997-2016